Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

ABSTRACT:

Background

There is no effective treatment strategy for advanced castration-resistant prostate cancer. Although Docetaxel (Taxotere®) represents the most active chemotherapeutic agent it only gives a modest survival advantage with most patients eventually progressing because of inherent or acquired drug resistance. The aims of this study were to further investigate the mechanisms of resistance to Docetaxel. Three Docetaxel resistant sub-lines were generated and confirmed to be resistant to the apoptotic and anti-proliferative effects of increasing concentrations of Docetaxel.

Results

The resistant DU-145 R and 22RV1 R had expression of P-glycoprotein and its inhibition with Elacridar partially and totally reversed the resistant phenotype in the two cell lines respectively, w

SUBMITTER: O'Neill AJ 

PROVIDER: S-EPMC3203088 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature